Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients.

Nassim Kamar 1, 2 Olivier Milioto 1 Laurent Alric 3 Labib El Kahwaji 1 Olivier Cointault 1 Laurence Lavayssière 1 Karine Sauné 4, 5 Jacques Izopet 4, 5 Lionel Rostaing 1, 5, *
* Auteur correspondant
1 Service de Néphrologie - Hypertension Artérielle Dialyse - Transplantation
2 I2MR - Institut de médecine moléculaire de Rangueil
3 Service de Gastro-entérologie - Hépatologie [Purpan]
4 Laboratoire de Virologie [Toulouse]
5 Centre de Physiopathologie Toulouse Purpan (ex IFR 30 et IFR 150)
Abstract : The aim of our study was to assess the efficacy and safety of entecavir in kidney- and liver-transplant recipients with chronic hepatitis B virus (HBV) infection. Ten male transplant patients with chronic HBV infection (eight kidney- and two liver-transplant patients), who have become adefovir (n=9) or lamivudine-resistant (n=1) were given entecavir at 0.5 to 1 mg/d. All patients were HBs Ag positive: six were HBe Ag(-)/HBe Ab(+), and four were HBe Ag(+)/HBe Ab(-). After a median follow-up of 16.5 months, entecavir therapy was associated with a significant decrease in HBV DNA viral load, that is, 3.86 (2.71-6.46) log10 copies/mL at baseline down to 2.94 (2.15-4) log10 copies/mL at last follow-up (P=0.004). Rate of HBV DNA clearance was 50% in both HBeAg(+) and HBeAg(-) patients. There were no significant changes in renal function or hematological parameters. This study demonstrates that entecavir therapy is safe and efficient in HBV(+) organ-transplant patients.
Type de document :
Article dans une revue
Transplantation, Lippincott, Williams & Wilkins, 2008, 86 (4), pp.611-4. 〈10.1097/TP.0b013e3181806c8c〉
Liste complète des métadonnées
http://www.hal.inserm.fr/inserm-00409078
Contributeur : Marie Francoise Simon <>
Soumis le : mercredi 5 août 2009 - 15:33:10
Dernière modification le : jeudi 13 septembre 2018 - 10:26:05

Identifiants

Collections

UNIV-TLSE3

Citation

Nassim Kamar, Olivier Milioto, Laurent Alric, Labib El Kahwaji, Olivier Cointault, et al.. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients.. Transplantation, Lippincott, Williams & Wilkins, 2008, 86 (4), pp.611-4. 〈10.1097/TP.0b013e3181806c8c〉. 〈inserm-00409078〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

191

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD